Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Announces Closing of Initial Public Offering

Business Wire May 3, 2017

IIROC Trade Resumption - Zymeworks Inc.

Newsfile April 28, 2017

IIROC Trade Halt - Zymeworks Inc.

Newsfile April 28, 2017

Zymeworks Announces Pricing of Initial Public Offering

Business Wire April 27, 2017

Zymeworks Files Registration Statement For Proposed Initial Public Offering

Business Wire April 3, 2017

Zymeworks Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

Business Wire March 13, 2017

Zymeworks Submits ZW25 Phase 1 Clinical Study Findings Abstract for ASCO 2017

Business Wire February 23, 2017

Zymeworks Receives Second Orphan Drug Designation for ZW25 in Gastric Cancer

Business Wire February 16, 2017

Zymeworks Appoints Dr. Kenneth Hillan and Hollings Renton to its Board of Directors

Business Wire February 14, 2017

Zymeworks Opens State-of-the-Art Lab Facility

Business Wire January 25, 2017

Zymeworks Announces the Successful Achievement of a Research Milestone with Lilly in Bispecific Antibody Collaboration

Business Wire January 5, 2017

Zymeworks to Present at the 2016 American Society of Hematology Annual Meeting and Exposition

Business Wire November 28, 2016

Zymeworks Inc. Announces the Addition of Lota S. Zoth to Its Board of Directors

Business Wire November 22, 2016

Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration

Business Wire September 28, 2016

Zymeworks Doses First Patient in Phase 1 Trial of ZW25, a Novel Bi-Specific Antibody for the Treatment of HER2-Expressing Cancers

Business Wire September 15, 2016

Zymeworks’ ZW25 and ZW33 Granted Orphan Drug Designation for Ovarian Cancer by U.S. Food and Drug Administration

Business Wire August 18, 2016

Zymeworks Receives FDA Acceptance of IND Application for ZW25, a Novel Bi-Specific Antibody, for the Treatment of HER2-Expressing Cancers

Business Wire August 18, 2016